# A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

> **NCT06770933** · PHASE2 · RECRUITING · sponsor: **Vantage Biosciences Ltd** · enrollment: 100 (estimated)

## Conditions studied

- Diabetic Retinopathy
- NPDR - Non Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** VX-01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06770933
- **Lead sponsor:** Vantage Biosciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-11
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770933, "A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06770933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*